CSIMarket Company Name, Ticker, Industry, else..
 
Arcellx Inc   (NASDAQ: ACLX)
Other Ticker:  
 
 
Price: $66.0000 $-0.51 -0.767%
Day's High: $66.67 Week Perf: -1.29 %
Day's Low: $ 64.90 30 Day Perf: 13.3 %
Volume (M): 515 52 Wk High: $ 107.37
Volume (M$): $ 33,957 52 Wk Avg: $70.39
Open: $64.90 52 Wk Low: $47.86



 Market Capitalization (Millions $) 3,647
 Shares Outstanding (Millions) 55
 Employees 22
 Revenues (TTM) (Millions $) 77
 Net Income (TTM) (Millions $) -162
 Cash Flow (TTM) (Millions $) -74
 Capital Exp. (TTM) (Millions $) 8

Arcellx Inc
Arcellx Inc is a biotechnology company that specializes in developing and commercializing cell therapies for cancer treatment. The company is focused on developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies that are engineered to target and eliminate cancer cells more effectively. Arcellx's technology is designed to enhance the safety and efficacy of CAR-T therapies by incorporating a controllable on-switch and off-switch mechanism, allowing for precise control of the therapy's activity. The company aims to revolutionize cancer treatment by providing more targeted and personalized therapies with improved outcomes for patients.


   Company Address: 800 Bridge Parkway Redwood City 94065 CA
   Company Phone Number: 327-0630   Stock Exchange / Ticker: NASDAQ ACLX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC        6.94% 
AMGN   -0.6%    
BCRX   -6.66%    
BIIB   -4.89%    
EXEL   -3.1%    
GILD   -1.19%    
• View Complete Report
   



Business Update

Arcellxs Positive iMMagine-1 Study Data Faces Market Scrutiny Amid Stagnant Share Performance

Published Mon, Dec 9 2024 8:19 AM UTC

Arcellx Inc. (NASDAQ: ACLX) has announced promising new data from its iMMagine-1 study, which evaluates the efficacy of its innovative therapies for patients with relapsed or refractory multiple myeloma. This significant data release is set for presentation during an oral session at the prestigious 66th Annual Meeting and Exposition of the American Society of Hematology (ASH...
Business Update

Pioneering Advances in CAR T-Cell Therapy for Multiple Myeloma Arcellx and Kites Breakthrough Developments

Published Tue, Nov 5 2024 4:36 PM UTC

In a rapidly evolving landscape of cancer therapeutics, cell therapies are heralding a new era of hope for patients battling difficult-to-treat malignancies. Among the promising developments in this domain is Arcellx s innovative approach to multiple myeloma (MM), a blood cancer notorious for its relapsing nature. This article delves into the significant strides made by Arce...
Business Update

Arcellx Inc. Showcases Robust Q2 2024 Performance, Driving Innovation in Immunotherapies and Solid Growth Trajectory...

Published Thu, Aug 8 2024 9:47 PM UTC

Arcellx Reports Promising Q2 2024 Results, Highlighting Advancements in Innovative Cell Therapies REDWOOD CITY, Calif. Arcellx, Inc. (NASDAQ: ACLX), a biotechnology leader recognized for its groundbreaking approaches to cell therapy, recently unveiled its financial results for the second quarter of 2024, marking a period of significant growth and development within the c...
Business Update

Arcellx and Kite Surge Forward with Revolutionary Anito-Cel Multiple Myeloma Program Amid Financial Hiccups

Published Fri, May 10 2024 12:47 AM UTC

Arcellx Inc. (NASDAQ: ACLX), based in Redwood City, California, and Kite, a Gilead Company (NASDAQ: GILD), based in Santa Monica, California, have announced their operational updates today on their jointly developed anitocabtagene autoleucel (anito-cel) multiple myeloma program. Despite facing a substantial decline in sequential revenue, Arcellx has continued to prioritize a...
Business Update

Arcellx and Kite Announce Advances in Multiple Myeloma Program, Introduce Global Phase 3 Trial for Innovative Anito-Cel Therapy

Published Thu, May 9 2024 8:47 PM UTC

Arcellx and Kite, a Gilead Company, recently provided updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program, showcasing significant progress in its development. The collaboration between the two companies aims to develop an innovative treatment option for multiple myeloma patients utilizing Arcellx s novel D-Domain binder. Multiple myeloma is a type...






Arcellx Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com